Worldwide reach for clinical trial supply services UK and Europe: We work closely with you to provide market insights needed in order to implement the best strategy to meet your commercial drug supply requirements. Our client testimonials attest to our unique, collaborative approach, which adds longstanding value and strong partnerships. Our aim is to understand your goals and to work to minimize waste, allowing you to reinvest those savings back into your R&D initiatives. We hold ourselves to the highest standards, delivering on time, and most importantly, with uncompromised quality and integrity. See even more information on https://www.clientpharma.com/what-we-do/biosimilars-and-reference-medicines/.
We profoundly understand and recognize the numerous risks associated with global drug procurement. We also appreciate the many complexities associated with worldwide storage and distribution of clinical trial supplies. Our team knows the importance of an efficient, robust supply chain — audited & approved — that promotes excellence, security and accountability. We provide batch traceability, supporting documentation (i.e. Certificates of Analysis (CofAs), Batch Release Certificates (BRCs), GMP Statements, stability data, Fit-for-Use (FFU) Statements, Certificates of Conformance (CofCs), Certificates of Origin (CofOs), etc.) and temperature monitoring data – delivering product pedigree and authenticity.
Our open and collaborative approach is tailored to you and your patients’ needs for every study. With dedicated points-of-contact and direct access to senior management, you are always in connection with us. Through regular business review meetings and custom KPIs, we never lose sight of what’s important to you, your team and your program. To learn more about how we can improve your clinical trial supply experience or receive a quote, please feel free to get in touch.
Our temperature-controlled capabilities include 2°- 8°C and 15°- 25°C facilities, as well as access to specialist transport to manage deliveries around the world according to product temperature requirements. Extensive capabilities: Our capabilities include stock receipt, import & export expertise, in-territory regulatory specialists, product reconciliation and destruction services. You can trust us: Our highly trained logistics team is dedicated to providing a robust clinical trial supply chain and trusted product integrity with regulatory compliant distribution through validated temperature-controlled logistics. We provide the peace-of-mind you need, offering you with dedicated clinical trial supply chain solutions to meet the explicit needs of your clinical programs. See even more details on https://www.clientpharma.com/.
Meeting the needs of global clinical supply trials requires diversity in supply strategies to address the unique complexities of each country’s healthcare and medication distribution systems. The “one-size fits all” approach is not a single supply strategy; instead, it leverages the expertise of a supply vendor partnership that addresses the need for a multi-faceted supply chain strategy. ClientPharma (CP) is a specialist global clinical trial supply company providing expertise in the procurement of comparators, rescue medications, adjuvant therapies, standard-of-care, reference drugs, medical devices, ancillaries, and matching placebos. From provision of clinical research samples to bulk supplies for global pivotal trials, the company has built a strong worldwide network to provide strategic commercial drug supply solutions for all stages of clinical programs. Reducing complexity and maximizing value – that’s our mission. CP is headquartered in the United Kingdom with offices and warehousing in the US, Ireland, Belgium, and China.
Forecasts by their very definition involve a degree of uncertainty. When a company fails to meet demand it can have major implications on the drug and the pharmaceutical company. The company may experience loss in sales, a bad reputation for unreliability with customers and overworked employees. It has been reported that where the drug itself is concerned, if the launch of a medicine is delayed due to a failure in estimation, it costs on average $15 million per drug, per day. Further research has also shown that a blockbuster drug will lose $1 billion in revenue annually until capacity is developed to meet demand. Overestimations in demand generally happen when the market is at its most volatile, or, if the reach of a new drug has been over estimated. These inaccuracies can cost companies. If a product’s demand is overestimated, companies have to find ways to correct their misjudgement by cutting the price of medicines which reduces margins and by making employees redundant to pay for the excess of stock. In some cases companies also have to destroy stock that has not been sold.